New data shows patients maintaining vision after a single intravitreal injection of gene therapy
Gene therapy is showing promise for one of the most common causes of blindness. Data presented today shows that six patients with wet age-related macular degeneration (AMD) have, so far, an average of eight months without the need for continued injections to control a disease that typically requires treatment every four to six weeks. Researchers say the hope is that gene therapy will free patients from nearly monthly eye injections by offering a potential “one-and-done” treatment. It’s not just about convenience; a more consistent treatment may also help people keep more of their vision. The research will be presented today at AAO 2019, the 123rd?Annual Meeting of the American Academy of Ophthalmology.
“This is potentially paradigm-shifting,” said lead researcher, Szilárd Kiss,?M.D., director of Clinical Research and chief of the Retina Service in the Department of Ophthalmology at Weill Cornell Medical College in New York City. “It’s the next revolutionary leap in treating AMD. When you think about what is science fiction and what is science reality; gene therapy for AMD is becoming a clinical reality.”
Dr. Kiss expects a gene therapy for wet AMD could be available within the next three to five years, depending upon the results of further clinical studies and regulatory approvals.
AMD is the most common cause of vision loss and blindness in Americans over age 50, affecting about 2.1 million people nationwide; a number that’s expected to explode as the population ages.
AMD is a degenerative eye disease that happens when part of the retina is damaged. The damage happens when new, weak blood vessels form behind the retina at the back of the eye. These abnormal vessels leak, causing scarring and killing off the cells that allow us to see.
The first revolutionary leap in AMD treatment occurred a little over a decade ago, with the introduction of a new medication called anti-VEGF therapy. It was the first treatment to inhibit the formation of those damaging, new blood vessels, allowing more than 90 percent of patients to keep their vision, according to clinical trials.
However, in the real world, the actual percentage is closer to 50 percent. One main reason why is that patients are undertreated. This is because most people with AMD must go to the ophthalmologist’s office every four to eight weeks for an injection directly into their eye (oftentimes in both eyes). This can be a difficult schedule to maintain for many elderly patients struggling with other maladies and reliant on others to get them to their ophthalmologist visits. It’s also unsustainable for the health care system. Last year alone, ophthalmologists performed more than 8 million anti-VEGF injections in the United States.
Researchers have been searching for a better alternative to monthly injections almost from the moment anti-VEGFs were introduced. Gene therapy is emerging as one of the more promising alternatives to long-term anti-VEGF treatment.
The goal of Dr. Kiss’ research is to develop a gene therapy that allows the eye to make its own anti-VEGF medicine. The ideal gene therapy would be administered not through a surgical procedure in an operating room, but through an injection into the eye that can be done in the doctor’s office, just like routine anti-VEGF treatment is done today.
To do this, Dr. Kiss and colleagues have developed a next-generation vector that can insert into the cells of the eye, genetic material that makes a molecule similar to a widely used anti-VEGF medicine called aflibercept. Once inside the cells, the DNA sequence begins making the aflibercept protein.
“Instead of taking a vial of aflibercept and injecting it into the eye, your eye makes the aflibercept,” Dr. Kiss explained. “The goal is a potential one-and-done treatment. You may need a booster once in a while, but this gene therapy could theoretically last a lifetime.”
In animal studies, Dr. Kiss and colleagues have shown that this gene therapy works just as well as an injection of aflibercept, with a favorable and manageable side-effect profile.
Dr. Kiss will be presenting today, early data on the first human subjects treated. The phase 1 clinical trial has thus far enrolled 12 patients who received a single injection of gene therapy for wet AMD. Prior to the study, the patients had received an average of 35 anti-VEGF injections; one patient had 109. After a single injection of gene therapy, no patient has required rescue treatment through an average of eight months (range, seven to 11 months).
The Latest on: Wet age-related macular degeneration
via Google News
The Latest on: Wet age-related macular degeneration
- RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degenerationon February 24, 2020 at 3:02 pm
About TOFU study A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 monotherapy and RBM-007 in ...
- Emergence of Dual VEGF and PDGF Antagonists in the Treatment of Exudative Age-Related Macular Degenerationon February 20, 2020 at 4:00 pm
Further clinical studies are necessary to evaluate safety and efficacy of dual VEGF/PDGF inhibitors in the treatment of wet AMD Age-related macular degeneration (AMD) is a major cause of visual ...
- Let's Talk About Wet Age-Related Macular Degenerationon February 19, 2020 at 11:49 pm
And as you read, you felt like you were literally losing letters on the page. It could be, you have wet AMD. Here’s what you should know about it. Age-related macular degeneration, or AMD, is a ...
- Let's Talk About Age-Related Macular Degenerationon February 19, 2020 at 2:29 pm
Age-related macular degeneration. It’s a mouthful, right ... Even if you have a progressive form of AMD (know as wet AMD), treatment is highly effective and any vision loss is contained to the central ...
- Wet Age-Related Macular Degeneration Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscapeon February 19, 2020 at 1:13 am
Wet AMD is a type of AMD characterized by the growth of abnormal blood vessels under the retina and macula. On the basis of product, the wet age-related macular degeneration market is categorized into ...
- RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degenerationon February 18, 2020 at 4:00 pm
First subject was administered with RBM-007 in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration RIBOMIC, Inc., a clinical stage ...
- Wet Age Related Macular Degeneration (AMD) Market 2020 Global Analysis, Opportunities And Forecast To 2025on February 18, 2020 at 6:22 am
Wiseguyreports.Com Adds “Wet Age Related Macular Degeneration (AMD) -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database Age-related macular ...
- Acuity Eye Group Encourages Eye Exams to Detect for Signs of Macular Degeneration during AMD Awareness Monthon February 17, 2020 at 6:00 am
February is age-related macular degeneration awareness month and Acuity Eye Group encourages people to get their regular eye exams. PASADENA, Calif. (PRWEB) February 17, ...
- Understanding Wet Age-Related Macular Degenerationon February 11, 2020 at 4:00 pm
Receiving a diagnosis of wet age-related macular degeneration (AMD) may explain what’s causing blurring, distortion, or missing spots in your vision, but it may prompt other questions ...
- UVa macular degeneration discovery provides potential to halt diseaseon February 1, 2020 at 1:00 pm
Researchers have successfully treated age-related macular degeneration in mice after finding an unexpected ... The discovery links the “dry” and “wet” forms of macular degeneration in a surprising way ...
via Bing News